Skip to content
Screener

GeneDx Holdings WGS Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$0
Azenta logo
AzentaAZTA
$0.01
Revvity logo
RevvityRVTY
$10.0%
NeoGenomics logo
NeoGenomicsNEO
CareDx logo
CareDxCDNA

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$2.3B-27.6%
Enterprise value$2.3B-27.0%
P/S5.2×-3.6×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001818331-26-000041
Line itemMarch 31, 2026 (Unaudited)December 31, 2025
Purchase commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 29,666,318 and 29,245,296 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively33
Additional paid-in capital1,690,2491,680,738
Accumulated deficit(1,436,811)(1,373,495)
Accumulated other comprehensive income683936
Total stockholders’ equity254,124308,182

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is GeneDx Holdings's common stock, par value (in dollars per share)?
GeneDx Holdings (WGS) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has GeneDx Holdings's common stock, par value (in dollars per share) changed year-over-year?
GeneDx Holdings's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for GeneDx Holdings's common stock, par value (in dollars per share)?
Over 4 years (2021 to 2025), GeneDx Holdings's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about GeneDx Holdings's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude